Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma.

Xiangke XinXiaojian ZhuYang YangNa WangJue WangJinhuan XuJia WeiLiang HuangMiao ZhengYi XiaoChunrui LiYang CaoFankai MengLijun JiangYicheng Zhang

Published in: Cellular oncology (Dordrecht, Netherlands) (2024)

PD1 inhibitor maintenance following CD19/22 CAR-T therapy obtained superior response and survival in r/r B-NHL, but not in the trial of CD19/22 CAR-T cell therapy combined with ASCT.

Keyphrases

cell therapy
stem cells
mesenchymal stem cells
acute lymphoblastic leukemia
acute myeloid leukemia
nk cells
clinical trial
study protocol
multiple myeloma
diffuse large b cell lymphoma
hodgkin lymphoma
phase iii
bone marrow